AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin amyloidosis (ATTR-PN). New guidance from health ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines ...

Of the 138 patients with ATTR-PN who completed a global open-label extension study of patisiran, the polyneuropathy disability scores either stayed the same or improved in 65% of patients. Treatment ...

In 2023, the agency declined to expand its indication to include wild-type or hereditary ATTR cardiomyopathy ... for hereditary transthyretin amyloidosis with polyneuropathy: a randomized clinical ...

Patients with ATTR-PN have a high rate of comorbidities and substantial direct healthcare and economic burdens, a study found.

Hereditary transthyretin amyloidosis ... to treat hATTR with polyneuropathy. In 2023, the agency declined to expand its indication to include wild-type or hereditary ATTR cardiomyopathy.

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...

People with transthyretin cardiac amyloidosis (ATTR-CA) on top of aortic stenosis ... and autonomic and peripheral neuropathy. "Recognizing these associated features could help clinicians identify ...

These included heart failure, cardiac arrhythmias, cardiomegaly, carpal tunnel syndrome, chronic kidney disease, and peripheral neuropathy. Recognizing these associated features ... Screening for ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company ...